SCHEMBL10001082

SCHEMBL10001082

COc1ccc(-c2cc(=O)c3c(OC)c(CO)c(CO)cc3o2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.65
MEN1 O00255 4/20 0.65
KMT2A Q03164 4/20 0.65
FLT3 P36888 4/20 0.63
MAPT P10636 6/20 0.61
NPC1 O15118 3/20 0.61
RAB9A P51151 3/20 0.61
POLB P06746 3/20 0.61
KIT P10721 1/20 0.61
NFKB1 P19838 1/20 0.61
OPRD1 P41143 1/20 0.61
NFKB2 Q00653 1/20 0.61
RELA Q04206 1/20 0.61
MAOB P27338 4/20 0.59
CYP19A1 P11511 1/20 0.59
ABCB1 P08183 2/20 0.57
CYP3A4 P08684 4/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
IP6K2 Q9UHH9 2/20 0.57
MAPK1 P28482 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10001085 0.88 MAPT (0.71) ALDH1A1MEN1KMT2AFLT3MAPT
SCHEMBL10001080 0.88 MAPT (0.64) ALDH1A1MEN1KMT2AFLT3MAPT
SCHEMBL10001089 0.88 FLT3 (0.69) ALDH1A1MEN1KMT2AFLT3MAPT
SCHEMBL10001084 0.86 ABCB1 (0.69) ALDH1A1MEN1KMT2AFLT3MAPT
SCHEMBL10001103 0.84 HSD17B2 (0.66) ALDH1A1MEN1KMT2AFLT3MAPT
SCHEMBL10001079 0.83 MAPT (0.67) ALDH1A1MEN1KMT2AFLT3MAPT
SCHEMBL11910055 0.82 ALDH1A1 (0.72) ALDH1A1MEN1KMT2AFLT3MAPT
SCHEMBL10001096 0.80 FLT3 (0.72) ALDH1A1MEN1KMT2AFLT3MAPT
SCHEMBL1973279 0.79 MEN1 (0.65) ALDH1A1MEN1KMT2AFLT3MAPT
SCHEMBL1976108 0.79 MEN1 (0.65) ALDH1A1MEN1KMT2AFLT3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120029066-A1 USE OF FLAVONES FOR TREATING PSYCHIATRIC DISORDERS WITH SENSORIMOTOR GATING DEFICITS TAIPEI MEDICAL UNIVERSITY (TW) 2012-02-02 US disclosed
US-20110243894-A1 METHODS OF TREATING HEPATITIS C VIRUS INFECTION KADMON CORPORATION, LLC 2011-10-06 US disclosed
US-20110243894-A1 METHODS OF TREATING HEPATITIS C VIRUS INFECTION KADMON CORPORATION, LLC 2011-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110243894-A1 METHODS OF TREATING HEPATITIS C VIRUS INFECTION HAVCR2, LIPC, FABP1 ALDH1A1 908/4885MEN1 4813/4885KMT2A 3148/4885
US-20120029066-A1 USE OF FLAVONES FOR TREATING PSYCHIATRIC DISORDERS WITH SENSORIMOTOR GATING DEFICITS HTR2C, GRIN2C, HTR5A ALDH1A1 1018/4885MEN1 4859/4885KMT2A 1058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.